Perfluoroperhydrophenanthrene (Vitreon) as a short-term vitreous substitute after complex vitreoretinal surgery.
Forty-one eyes underwent surgery for complex vitreoretinal disease, with perfluoroperhydrophenanthrene (Vitreon) used as an intraoperative tool and postoperative vitreous substitute. Postoperative use of Vitreon ranged from 3 days to 9 weeks (mean, 3.3 weeks). All retinas were reattached intraoperatively; 73% remained attached after the initial surgery. The final macular attachment rate was 100% after additional surgery. Four eyes that received a combination of Vitreon and silicone oil for simultaneous superior and inferior tamponade were successfully reattached after the initial procedure. Visual acuity improved or remained stable in 80% of the eyes. No toxic effects directly attributable to Vitreon were observed. Mean follow up was 9 months.
Tanji
T M
TM
LSU Eye Center, Louisiana State University Medical Center School of Medicine, New Orleans 70112-2234.
Peyman
G A
GA
Mehta
N J
NJ
Millsap
C M
CM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005128:Eye Diseases / Q000601:surgery; D005260:Female; D005466:Fluorocarbons; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D019736:Prostheses and Implants; D012163:Retinal Detachment / Q000601:surgery; D012164:Retinal Diseases / Q000601:surgery*; D012827:Silicone Oils; D014792:Visual Acuity; D014822:Vitreous Body / Q000601:surgery*
D005466:Fluorocarbons; D012827:Silicone Oils; C047722:perfluorophenanthrene